semaglutide and fda US approves weight loss drug Wegovy to prevent cardiovascular events Semaglutide: The benefits and risks

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management and chronic weight management

Autoimmune disease and systemic infections like tuberculosis can lead to more persistent lymph node enlargement

For anyone battling brain fog or seeking to optimize their mental performance, glutathione IV therapy offers a science-backed approach that addresses cognitive health at the cellular level where it matters most

Lilly has indicated that they expect to have final Phase 3 data by 2025, if everything goes as planned

We adopted Giemsa staining (Methods and Extended Data Fig